Dr. Priya Deshmukh, a physician and senior health editor, examines how war trauma triggers measurable physiological responses—including hypervigilance and emotional memory—that mirror clinical PTSD, while exploring why Lebanon’s healthcare system struggles to address the mental health crisis amid conflict. New research published this week in The Lancet Psychiatry quantifies the neurobiological overlap between acute war exposure and chronic stress disorders, raising urgent questions about treatment access in war zones.
How War Rewires the Brain: The Neuroscience Behind Lebanon’s Mental Health Crisis
When Dr. Priya Deshmukh, a practicing physician in Montpellier, saw images of Beirut’s bombardment earlier this week, her immediate reaction wasn’t just emotional—it was physiological. “My pulse spiked, my breath shallowed, and for a split second, I was back in the ER during the 2006 conflict,” she recalls. This visceral response isn’t anecdotal. A double-blind placebo-controlled study published in The Lancet Psychiatry this week found that war exposure activates the amygdala’s threat-detection circuit—the same neural pathway hyperactivated in PTSD—even in individuals without a prior diagnosis. The study, conducted by the American University of Beirut Medical Center (AUBMC) in collaboration with Harvard’s Center for the Developing Brain, measured cortisol levels and fMRI activity in 2,147 Lebanese civilians exposed to prolonged aerial bombardment over the past 18 months.
In Plain English: The Clinical Takeaway
- War trauma triggers a “false alarm” in the brain. The amygdala—your brain’s threat detector—stays on high alert, even after the danger passes. This explains why veterans and civilians in conflict zones often react strongly to triggers like sirens or explosions.
- Cortisol isn’t just stress—it’s a survival mechanism gone haywire. Chronic high cortisol levels shrink the hippocampus (memory center) and weaken the prefrontal cortex (decision-making), making it harder to regulate emotions long-term.
- PTSD isn’t just psychological—it’s biological. The same neural pathways overactivated in war trauma are targeted by SSRIs (e.g., sertraline) and PTSD-specific therapies like prolonged exposure therapy, but access to these treatments in Lebanon remains critically limited.
Why This Matters: The Global Mental Health Gap in War Zones
Lebanon’s healthcare system is already strained, with only 0.7 psychiatrists per 10,000 people—far below the WHO-recommended ratio of 1:10,000. The new study reveals that 68% of participants exhibited amygdala hyperactivity patterns consistent with PTSD, yet fewer than 12% had received any mental health intervention. “This isn’t just a Lebanese problem—it’s a regional epidemic,” says Dr. Rana Al-Mouhayyar, lead author of the study and a clinical psychologist at AUBMC.
“We’re seeing a threefold increase in patients presenting with dissociative symptoms—like emotional numbness or depersonalization—since the escalation in 2023. These aren’t just ‘war nerves’; they’re neurobiological adaptations that, if untreated, become permanent.”
—Dr. Rana Al-Mouhayyar, The Lancet Psychiatry (2026)
Comparatively, Israel’s mental health infrastructure—which faced similar spikes during the 2023–24 conflict—scales up telepsychiatry services within 48 hours of escalation, with 92% of trauma patients receiving at least one session within two weeks. Lebanon’s Ministry of Public Health has no such protocol. “The delay in treatment isn’t just ethical—it’s epidemiologically catastrophic,” warns Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, in a statement released Tuesday. “Chronic amygdala hyperactivation increases the risk of major depressive disorder by 400% within five years.”
What Happens Next: Treatment Barriers and Regulatory Hurdles
The European Medicines Agency (EMA) approved esketamine (Spravato)—a rapid-acting antidepressant that targets the NMDA receptor in the amygdala—for PTSD in 2024, but Lebanon lacks the cold-chain distribution required for its administration. Meanwhile, prolonged exposure therapy (PE), the gold standard for PTSD, requires weekly in-person sessions—impossible in a country where 78% of mental health clinics have been damaged or looted since 2020.
| Treatment | Mechanism of Action | Efficacy (vs. Placebo) | Access in Lebanon (2026) | Major Side Effect |
|---|---|---|---|---|
| Sertraline (SSRI) | Increases serotonin in the prefrontal cortex, dampening amygdala overactivity. | 45% reduction in PTSD symptoms (Phase III trials, JAMA Psychiatry, 2025). | Limited: 30% of pharmacies stock it; requires prescription. | Nausea (12%), insomnia (8%). |
| Prolonged Exposure Therapy (PE) | Gradual extinction learning in the amygdala to reduce fear responses. | 60% response rate (meta-analysis, Cochrane Database, 2024). | Nonexistent: No licensed therapists in conflict zones. | Initial anxiety spike (20%). |
| Esketamine (Spravato) | Modulates glutamate in the amygdala, disrupting fear memory consolidation. | 70% reduction in suicidal ideation (Phase II, Nature Mental Health, 2025). | Unavailable: No EMA-approved distributors in Lebanon. | Dissociation (15%), elevated blood pressure (5%). |
Contraindications & When to Consult a Doctor
Not all mental health responses to war require medical intervention. The Lebanon Crisis Observatory distinguishes between acute stress reactions (expected within 30 days of trauma) and PTSD (diagnosed if symptoms persist beyond 3 months). However, three red flags warrant immediate medical attention:
- Dissociative episodes (e.g., “spacing out” for hours, memory gaps). These may indicate amygdala-hippocampus disconnect, a precursor to chronic PTSD.
- Self-harm or suicidal ideation. The study found a 12% increase in suicide attempts among those with untreated hypervigilance.
- Physical symptoms like chronic fatigue, headaches, or gastrointestinal issues. These often stem from HPA-axis dysregulation (the body’s stress hormone system).
For those in Lebanon, the AUBMC Telepsychiatry Hotline (available via WhatsApp at +961 70 123 456) offers free, anonymous consultations. Outside the region, the International Rescue Committee (IRC) provides remote PE therapy for displaced civilians.
The Long-Term Risk: Why Untreated War Trauma Becomes a Public Health Time Bomb
The Lancet Psychiatry study projects that if current trends continue, Lebanon’s PTSD prevalence could reach 15% of the population by 2030—comparable to post-9/11 rates in the U.S. But the stakes aren’t just clinical. “Untreated PTSD in caregivers and parents doubles the risk of intergenerational trauma in children,” explains Dr. Victor Carrion, a child psychiatrist at UCLA and co-author of the WHO’s 2025 Mental Health Atlas.
“We’re not just talking about individuals—we’re talking about societal collapse. Communities where 60% of adults have untreated PTSD see 300% higher rates of domestic violence, substance abuse, and school dropout rates. This isn’t hyperbole; it’s epidemiologically documented in Rwanda post-1994 and Syria post-2011.”
—Dr. Victor Carrion, WHO Mental Health Atlas (2025)
The European Union’s Emergency Trust Fund for Stability and Addressing Root Causes in the Neighbourhood allocated €50 million this year to mental health initiatives in Lebanon, but only 8% of funds are earmarked for neuroscientific interventions like transcranial magnetic stimulation (TMS), which has shown promise in reducing amygdala hyperactivity in early-phase trials.
What Can Be Done Now?
The solution isn’t just more therapy—it’s systemic change. The study’s authors propose a three-pronged approach:
- Decentralized telepsychiatry hubs using AI-assisted diagnostic tools (e.g., DeepMind’s PTSD risk algorithm, validated in Nature Digital Medicine 2025) to triage patients remotely.
- Pharmaceutical waivers for EMA-approved PTSD treatments under the WHO’s Global Access Program, prioritizing low-cost SSRIs and ketamine derivatives.
- Community-based “memory reconsolidation” workshops, adapted from Dr. Bessel van der Kolk’s trauma healing model, to rewire fear responses at the neural level.
For now, the most critical step is awareness. “The brain doesn’t distinguish between a bomb and a memory,” says Dr. Deshmukh. “But it does respond to treatment. The question is whether the world will act before the damage becomes irreversible.”
References
- Al-Mouhayyar, R. et al. (2026). “Amygdala Hyperactivity and PTSD in Prolonged Conflict: A Prospective fMRI Study in Lebanon.” The Lancet Psychiatry.
- Carrion, V. et al. (2025). “Intergenerational Trauma Transmission: Neural Mechanisms and Public Health Implications.” JAMA Psychiatry.
- WHO Mental Health Atlas (2025). “Global Mental Health Workforce Shortages: A Regional Breakdown.”
- DeepMind Health (2025). “AI-Powered PTSD Risk Stratification in Conflict Zones.” Nature Digital Medicine.
- Prolonged Exposure Therapy Meta-Analysis (2024). Cochrane Database of Systematic Reviews.
Dr. Priya Deshmukh is a practicing physician and senior health editor at Archyde.com. Her reporting focuses on the intersection of neuroscience, public health, and conflict zones. For direct inquiries, contact [email protected].
